Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers

ESMO Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers 2024 Ovarian Cancer Pancreatic Cancer Prostate Cancer Triple Negative Breast Cancer